Johnson & Johnson announced on Thursday that its monoclonal antibody Tremfya had demonstrated superiority over Stelara, another of its drugs, in a phase 3 clinical trial for Crohn's disease.

According to J&J, its immunotherapy proved superior to placebo and Stelara in the two modes of administration tested (200 mg every four weeks and 100 mg every eight weeks).

The study involved adult patients with a moderate to severe form of the disease.

For Professor Remo Panaccione of the University of Calgary, principal investigator of the trial, these results are 'promising' for patients who experience persistent symptoms after failure of previous therapies.

Tremfya is already approved in several countries for the treatment of plaque psoriasis, in adults who are candidates for systemic therapy or phototherapy, and in psoriatic arthritis.

Copyright (c) 2024 CercleFinance.com. All rights reserved.